Chemotherapy-induced Peripheral Neuropathy (CIPN), Early-Stage Breast Carcinoma, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Taxane-induced Peripheral Neuropathy
Conditions
Keywords
Chemotherapy-induced peripheral neuropathy (CIPN), Acupuncture, Early-Stage Breast Carcinoma, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Brief summary
This study is being done to evaluate the potential benefits of using acupuncture to reduce symptoms of tingling, burning, numbness and pain in the hands and feet of women with peripheral neuropathy after completion of chemotherapy for breast cancer.
Detailed description
Chemotherapy drugs used to treat cancer can cause temporary or permanent damage to the nerves in the hands and feet, a condition called "chemotherapy-induced peripheral neuropathy". The most common symptoms of chemotherapy-induced peripheral neuropathy are pain, tingling, burning or numbness sensation, which can lead to balance problems or trouble using fingers or pick up/holding things. These symptoms often last months to years after the completion of chemotherapy. Medications and nutritional supplements can ease the symptoms of chemotherapy-induced peripheral neuropathy, but many patients continue to experience symptoms despite these treatments. Acupuncture is an intervention in which hair-thin, stainless steel needles are shallowly inserted into specific points on the skin, with the goal of influencing the body's natural healing system. Acupuncture has been studied in clinical trials in cancer patients and has been shown to be effective for various conditions including chemotherapy-induced nausea and vomiting. A few preliminary studies have suggested that acupuncture may help to reduce symptoms of peripheral neuropathy, but more information is needed about the benefits of acupuncture in breast cancer patients This study is being done to evaluate the potential benefits of using acupuncture to reduce symptoms of tingling, burning, numbness and pain in the hands and feet of women with peripheral neuropathy after completion of chemotherapy for breast cancer. This research study will help to determine the benefits of acupuncture for the treatment of chemotherapy-induced peripheral neuropathy. The study will also look at two different acupuncture schedules to determine whether patients derive benefits from lower and higher dose acupuncture treatments.
Interventions
PROCEDUREImmediate Acupuncture Group
PROCEDUREDelayed Acupuncture Group
Sponsors
Dana-Farber Cancer Institute
The Comprehensive and Integrative Medicine Institute of South Korea
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* History of histologically or cytologically proven breast cancer at stage I, II and III, without evidence of distant metastasis; * Completed adjuvant taxane-based chemotherapy as single agents or in combination with platins or HER-2 directed therapy * Reporting grade 1 or greater of the following symptoms persistently for more than 2 weeks: neuropathic pain, allodynia, areflexia, dysesthesia, paresthesia, hyperesthesia, hypoesthesia or glove and stocking syndrome as defined by Common Terminology Criteria for Adverse Events (CTCAE v. 4.03) (Table 1 and the screening checklist); * Patients who are currently on stable prescription medications or dietary supplements for CIPN and still symptomatic as defined above will be allowed to participate in the study. Related medications are: gabapentin, pregabalin, nortriptyline, amitriptyline, duloxetine, venlafaxine; lidocaine, opioid tramadol and other narcotics; NSAIDs; glutamine, glutathione, vitamin E and vitamin B12; * Age ≥ 18 years; * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; * Adequate hematological function: neutrophil count \>1.0 x109/L, platelet count \>50x109/L; * Signed informed consent.
Exclusion criteria
* Patients with any of the following criteria will not be eligible for the study: * Unstable cardiac disease or myocardial infarction within 6 months prior to study entry; * Wearing a pacemaker or implantable cardioverter-defibrillator; uncontrolled seizure disorder; * History of pre-existing peripheral neuropathy prior to chemotherapy, including alcoholism, vitamin B deficiency, diabetes, HIV, congenital neuropathy, toxic neuropathy; * Peripheral neuropathy caused by tumor infiltration or compression of spinal nerves or surgical trauma; * Pregnancy or potential pregnancy and nursing; * Active clinically significant uncontrolled infection; * Prior use of acupuncture for CIPN within 6 months prior to study entry; * Patients with uncontrolled major psychiatric disorders, such as major depression or psychosis, will not be eligible for this trial. Patients with a history of depression or anxiety who are stable on or off psychiatric medications will be eligible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response Rate from Baseline in PNQ Score | Baseline, Week 8 | The PNQ includes two questionnaire items: one asking about sensory neurotoxicity and the other asking about motor neurotoxicity. The questionnaire items correspond to the neurotoxicity questions included in the NCI-CTCAE. PNQ grades range from grade A (no neuropathy) to grade E (very severe neuropathy). Answer options will be coded 0=A to 4=E, with a higher score indicating more severe CIPN |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in FACT/NTX subscale baseline to 8 weeks | Baseline, 8 Weeks | — |
| Changes in EORTC-QLQ-CIPN20 subscale Baseline, 8 Weeks | Baseline, 8 Weeks | Comprised of three subscales assessing sensory, motor, and autonomic symptoms. Subscale scores will be calculated and linearly transformed to a 0 to 100 scale, with higher scores suggesting more severe symptoms. Changes from baseline (8-week - baseline) between the intervention arms for each subscale will be of interest. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORWeidong Lu, M.B., MPH, Ph.D
Dana-Farber Cancer Institute
Outcome results
None listed